{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:26:39Z","timestamp":1779229599341,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ygyno.2019.05.030","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T12:06:33Z","timestamp":1559909193000},"page":"426-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9460-9399","authenticated-orcid":false,"given":"Barbara N.","family":"Harding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata R.","family":"Urban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel S.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.05.030_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2016.12.031","article-title":"Unknown face of known drugs - what else can we expect from angiotensin converting enzyme inhibitors?","volume":"797","author":"Wzgarda","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.05.030_bb0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ijc.30066","article-title":"Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer","volume":"139","author":"Huang","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2019.05.030_bb0015","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.canep.2013.09.001","article-title":"Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study","volume":"37","author":"Holmes","year":"2013","journal-title":"Cancer Epidemiol."},{"issue":"11","key":"10.1016\/j.ygyno.2019.05.030_bb0020","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2019.05.030_bb0025","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/1078-0432.CCR-04-1946","article-title":"Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination","volume":"11","author":"Suganuma","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2019.05.030_bb0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2015.10.025","article-title":"Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts synergistic anti-cancer effect with glycolysis inhibition","volume":"370","author":"Ju","year":"2016","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.ygyno.2019.05.030_bb0035","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0735-1097(99)00447-7","article-title":"Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?","volume":"34","author":"Mason","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.05.030_bb0040","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1535-7163.MCT-15-0456","article-title":"T-type Ca2+ channel inhibition sensitizes ovarian cancer to carboplatin","volume":"15","author":"Dziegielewska","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.ygyno.2019.05.030_bb0045","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/07357907.2011.568565","article-title":"Blockade of T-type Ca(2+) channels inhibits human ovarian cancer cell proliferation","volume":"29","author":"Li","year":"2011","journal-title":"Cancer Investig."},{"issue":"24","key":"10.1016\/j.ygyno.2019.05.030_bb0050","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.bmcl.2013.10.049","article-title":"In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers","volume":"23","author":"Jang","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ygyno.2019.05.030_bb0055","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/ncomms2413","article-title":"Src activation by beta-adrenoreceptors is a key switch for tumour metastasis","volume":"4","author":"Armaiz-Pena","year":"2013","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ygyno.2019.05.030_bb0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1078-0432.CCR-05-1698","article-title":"Stress hormone-mediated invasion of ovarian cancer cells","volume":"12","author":"Sood","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.05.030_bb0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/CLEP.S33695","article-title":"Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint","volume":"4","author":"Fitzgerald","year":"2012","journal-title":"Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.ygyno.2019.05.030_bb0070","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1055\/s-0042-115016","article-title":"The clinical relevance of beta blockers in ovarian carcinoma","volume":"76","author":"Hefner","year":"2016","journal-title":"A Systematic Review. Geburtshilfe Frauenheilkd"},{"issue":"1","key":"10.1016\/j.ygyno.2019.05.030_bb0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13058-015-0655-3","article-title":"beta2-adrenoceptor signaling regulates invadopodia formation to enhance tumor cell invasion","volume":"17","author":"Creed","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2019.05.030_bb0080","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1755-5922.2011.00306.x","article-title":"Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity","volume":"31","author":"Ladage","year":"2013","journal-title":"Cardiovasc. Ther."},{"issue":"5","key":"10.1016\/j.ygyno.2019.05.030_bb0085","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.ygyno.2019.05.030_bb0090","article-title":"Current gaps in ovarian cancer epidemiology: the need for new population-based research","volume":"109","author":"Epidemiology Working Group Steering Committee","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"8 Suppl","key":"10.1016\/j.ygyno.2019.05.030_bb0095","first-page":"IV","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med. Care"},{"issue":"11","key":"10.1016\/j.ygyno.2019.05.030_bb0100","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1002\/1097-0142(19951201)76:11<2343::AID-CNCR2820761124>3.0.CO;2-#","article-title":"Completeness of hospital cancer case reporting from the SEER program of the National Cancer Institute","volume":"76","author":"Zippin","year":"1995","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2019.05.030_bb0105","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am. J. Epidemiol."},{"issue":"6 Pt 1","key":"10.1016\/j.ygyno.2019.05.030_bb0110","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1111\/1475-6773.12073","article-title":"How medicare part D benefit phases affect adherence with evidence-based medications following acute myocardial infarction","volume":"48","author":"Stuart","year":"2013","journal-title":"Health Serv. Res."},{"issue":"7","key":"10.1016\/j.ygyno.2019.05.030_bb0115","first-page":"488","article-title":"Using medicare data for comparative effectiveness research: opportunities and challenges","volume":"17","author":"Fung","year":"2011","journal-title":"Am. J. Manag. Care"},{"issue":"6","key":"10.1016\/j.ygyno.2019.05.030_bb0120","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jhealeco.2013.04.007","article-title":"Digesting the doughnut hole","volume":"32","author":"Joyce","year":"2013","journal-title":"J. Health Econ."},{"issue":"8 Suppl","key":"10.1016\/j.ygyno.2019.05.030_bb0125","article-title":"Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations","volume":"40","author":"Bach","year":"2002","journal-title":"Med. Care"},{"issue":"5","key":"10.1016\/j.ygyno.2019.05.030_bb0130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/aje\/kwf068","article-title":"Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the public health disparities geocoding project","volume":"156","author":"Krieger","year":"2002","journal-title":"Am. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.ygyno.2019.05.030_bb0135","first-page":"1092","article-title":"Measures of racial\/ethnic health disparities in cancer mortality rates and the influence of socioeconomic status","volume":"99","author":"Chu","year":"2007","journal-title":"J. Natl. Med. Assoc."},{"key":"10.1016\/j.ygyno.2019.05.030_bb0140","unstructured":"United States Department of Agriculture (2016) Rural urban continuum codes. http:\/\/www.ers.usda.gov\/data-products\/rural-urbancontinuum-codes.aspx. Accessed April."},{"issue":"6","key":"10.1016\/j.ygyno.2019.05.030_bb0145","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ygyno.2019.05.030_bb0150","unstructured":"CMS Medicare and Medicaid Research Data. Chronic Conditions Data Warehouse. Available: https:\/\/www.ccwdata.org\/."},{"issue":"6","key":"10.1016\/j.ygyno.2019.05.030_bb0155","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.109.139279","article-title":"Validation of a case definition to define hypertension using administrative data","volume":"54","author":"Quan","year":"2009","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.ygyno.2019.05.030_bb0160","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1524-6175.2007.07146.x","article-title":"Treatment of hypertension and dyslipidemia or their combination among US managed-care patients","volume":"9","author":"Dutro","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"10.1016\/j.ygyno.2019.05.030_bb0165","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.0000222373.59104.3d","article-title":"Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data","volume":"47","author":"Halpern","year":"2006","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ygyno.2019.05.030_bb0170","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat. Methods Med. Res."},{"issue":"5","key":"10.1016\/j.ygyno.2019.05.030_bb0175","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/aje\/kwp425","article-title":"Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation","volume":"171","author":"Lee","year":"2010","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.05.030_bb0180","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1037\/1082-989X.7.2.147","article-title":"Missing data: our view of the state of the art","volume":"7","author":"Schafer","year":"2002","journal-title":"Psychol. Methods"},{"issue":"19","key":"10.1016\/j.ygyno.2019.05.030_bb0185","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/jnci\/djt211","article-title":"Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival","volume":"105","author":"Chubak","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.ygyno.2019.05.030_bb0190","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/sim.4780020222","article-title":"The need for randomization in the study of intended effects","volume":"2","author":"Miettinen","year":"1983","journal-title":"Stat. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2019.05.030_bb0195","first-page":"469","article-title":"History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium","volume":"28","author":"Minlikeeva","year":"2017","journal-title":"Cancer Causes Control"},{"issue":"6","key":"10.1016\/j.ygyno.2019.05.030_bb0200","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jamda.2016.01.015","article-title":"Changes in prescribed drugs between admission and the end of life in patients admitted to palliative care facilities","volume":"17","author":"van Nordennen","year":"2016","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"2","key":"10.1016\/j.ygyno.2019.05.030_bb0205","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5468\/ogs.2017.60.2.170","article-title":"Perioperative administration of propranolol to women undergoing ovarian cancer surgery: a pilot study","volume":"60","author":"Jang","year":"2017","journal-title":"Obstet Gynecol Sci"},{"key":"10.1016\/j.ygyno.2019.05.030_bb0210","unstructured":"ClinicalTrials.gov. Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients. Available at: clinicaltrials.gov\/ct2\/show\/NCT01308944. Accessed December."},{"key":"10.1016\/j.ygyno.2019.05.030_bb0215","author":"ClinicalTrials.gov"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819312740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819312740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:44:57Z","timestamp":1758771897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819312740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0090825819312740"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.030","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}